Rationale Therapie der Hitzewallungen unter Hormonentzugsbehandlung bei Patienten mit fortgeschrittenem Prostatakarzinom

Deutsche Medizinische Wochenschrift

Volumn 122, Issue 30, 1997, Pages 944-945

  Kliesch, S ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646832611     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Atala, A., M. Amin, J. I. Harty Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle stimulating hormone, luteinizing hormone and testosterone. Urology 39 (1992), 108-110.
2. Aubert, J., V. Vigouroux, B. Doré Les bouffées de chaleur de l'homme après castration chirurgicale ou médicamenteuse. Progrès en Urologie 5 (1995), 507-509.
3. Bailar, J. C., D. P. Byar, and The Veterans Administration Coopérative Urological Research Group Estrogen treatment for cancer of the prostate. Cancer 26 (1970), 257-261.
4. Behre, H. M. Klinisch-experimentelle Studien zur reversiblen Suppression der Gonadotropin- und Testosteronsekretion durch den GnRH-Antagonisten Cetrorelix beim Mann. Habilitationsschrift, Westfälische Wilhelms-Universität Münster. 1995.
5. Behre, H. M., E. Nieschlag Testes. In Reinwein, D., G. Benker (Hrsg.) Klinische Endokrinologie (Schattauer Stuttgart 1992), 251-297.
6. Behre, H. M., A. Böckers, A. Schlingheider, E. Nieschlag Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH-antagonist cetrorelix over 8 days in normal men. Clin. Endocrinol. 40 (1994). 241 -248.
7. Behre, H. M., S. Kliesch, D. Meschede, E. Nieschlag Hypogonadismus und Infertilität des Mannes. In Gerok. W., F. Hartmann. M. Pfreundschuh.T. Philipp, H. P. Schuster, G.W. Sybrecht (Hrsg.) Kli-nik der Gegenwart III, 2 (Urban und Schwarzenberg München 1994), 1-73.
8. Biermann, C. W. Lebensqualität. In Rübben, H. (Hrsg.) Uroonkologie (Springer Berlin 1997), 871 -882.
9. Buchholz, N. P., G. Mattarelli Hot flashes after orchiectomy in treatment of prostate cancer. Z. Gerontol. 27 (1994), 334-336.
10. Casper, R. F., S. C. C. Yen Neuroendocrinology of menopausal Hushes. Clin. Endocrinol. 22 (1985), 293 -312.
11. Charig, C. R., J. S. Rundle Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33 (1989), 175-178.
12. Corson, S. L A decade of experience with transdermal estrogen replacement therapy. Int.J. Fertil. 38 (1993), 79-91.
13. Crawford.J. S. Hot flushes and cold turkey. Brit. med.J. (1977), 1599.
14. '"Crawford, E. D., E. P. DeAntonio, F. Labrie, F. H. Schröder, J. Geller Therapeutic controversies. Endocrine therapy of prostate cancer. Optimal form and appropriate timing. J. Gin. Endocrinol. Metab. 80(1995), 1062-1078.
15. Decensi. A. U., F. Boccardo. D. Guarneri, N. Positano. M. C. Paoletti, M. Costantini, G. Martorana;, L Giuliani (for the Italian Prostatic Cancer Project) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J. Urol. 146 (1991). 377-381.
16. Delaere, K. P. J., E. L Van-Thillo Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin. Oncol. 18 Suppl.6.(1994),13-18.
17. Denis, L J., J. L Carneiro De Moura, A. Bono, R. Sylvester. R. Whelan, D. Newling, M. DePauw. Members of the EORTC GU Group and EORTC Data Center Goserelin acetate and flutamide versus bilateral orchiectomy. Urology 42 (1993), 119-129.
18. DeVane, G. W. Catecholamine-opioid interactions. Sem. Reprod. Endocrinol. 5 (1987). 135-144.
19. DeVoogt, H.J., P. H. Smith, M. Pavone-Macaluso. M. DePauw, S. Suciu and Members of the European Organization for Research on Treatment of Cancer Urological Group Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer. J. Urol. 135 (1986). 303-307.
20. Dodds, E. C., L Goldberg, W. Lawson Oestrogenic activity of certain oestrogenic compounds. Nature 141 (1938), 247-248.
21. Eaton, A. C., N. McGuire Cyproterone acetate in treatment of post-orchidectomy hot flushes. Lancet (1983). 1336-1337.
22. Forti. G., C. Selli Prospects for prostatic cancer incidence and treatment by the year 2000. Int.J. Androl. 19 (1996), 1 -10.
23. Fossa, S. D., N. Aass, S. Opjordmoen. Assessment of quality of life in patients with prostate cancer. Semin. Oncol. 21 (1994), 657-661.
24. Frödin, T., G. Alund, E. Varenhorst Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 7 (1985), 203-208.
25. Gambone, J., D. R. Meldrum. L Laufer, R. J. Chang, J. K. H. Lu, H. L. Judd Further delineation of hypothalamic dysfunction responsible for menopausal hot flashes. J. Clin. Endocrinol. Metab. 59 (1984), 1097-1102.
26. Ginsburg,J., B. O'Reilly Climacteric flushing in a man. Brit. Med. J. 287 (1983), 262.
27. Griffiths. K., C. L Eaton. M. E. Harper. A. Turkes. W. B. Peeling Hormonal treatment of advanced disease some newer aspects. Oncol. 21 (1994), 672-687.
28. Grossman, A. Opioid peptides and reproductive function. Sem. Reprod. Endocrinol. 5 (1987). 115-124.
29. Gunnarsson, P. O., G. Plym Forshell, A. Fritjofsson, B. J. Norlen Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt). Scand. J. Urol. Nephrol. 15 (1991). 201-205.
30. Haapiainen, R., S. Rannikko, 0. Alfthan and the Finnprostate Group Comparison of primary orchidectomy and polyestradiol phosphate in the treatment of advanced prostatic cancer. Brit. J. Uro!.66(1990),94-97.
31. 3i Heuzeroth, L., D. Gruneklee Clonidine. An alternative in the treatment of delirium tremens. Med. Klin. 83 (1988), 783-789.
32. Jewelewicz, R. New developments in topical estrogen therapy. Fertil. Steril. 67 (1997), 1-12.
33. Kaisary, A. V., C J. Tyrrel, W. B. Peeling, K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Brit.J. Ural. 67 (1991), 502-508.
34. Karling, P., M. Hammar, E. Varenhorst Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J. Urol. 152(1994), 1170-1173.
35. Kramer, P., N. Andrzejak-Nolten, G. Kallischnigg, F. Neumann Prevention of hot flushes with CPA in the hormonal treatment of prostatic cancer. In »3 rd international symposium on recent advances in urological cancer diagnosis and treatment.« (Paris 1992), 111-115.
36. Kronenberg, F. Hot flashes. Epidemiology and physiology. Ann. N. Y. Acad. Sci. 592 (1990), 123 -133.
37. Leitenberger, A., J. E. Altwein Pathophysiologie und Behandlungsmöglichkeiten von Hitzewallungen nach Sexualsteroidentzug. Eine Übersicht. Urologe [B] 33 (1993). 27-31.
38. The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl. J. Med. 311 (1984). 1281-1286.
39. Lightman, S. L., H. S. Jacobs, A. K. Maguire Down-regulation of gonadotrophin secretion in postmenopausal women by a superactive LHRH analogue. Brit.J. Obstet. Gynaecol. 89 (1982), 977-980.
40. Loprinzi, C. L., R. M. Goldberg. J. R. O'Fallon, S. K. Quella, A. W. Miser, L A. Mynderse, L D. Brown, L K. Tschetter, M. B. Wilwerding, A. M. Dose, J. E. Oesterling Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J. Urol. 151 (1994), 634-636.
41. Loprinzi, C. L,J. C. Michalak. S. K. Quella, J. R. O'Fallon, A. K. Hatfield, R. A. Neiimark, A. M. Dose, T. Fischer, C.Johnson, N. E. Klatt, W. W. Bate, R. M. Rospond, J. E. Oesterling Megestrol acetate for the prevention of hot flashes. New Engl. J. Med. 331 (1994), 347-352.
42. Martoccia, D., F. Mastandrea, J. Lockhart, L Persky Estrogen substitution for (LHRH) agonists. Immediate effect on PSA. Proc. Amer. Urol. Assoc. 155 (1996), 578 A.
43. Miller, J. I., F. R. Ahmann Treatment of castration-induced menopausal symptoms with low dose of diethylstilbestrol in men with advanced prostate cancer. Urology 40 (1992), 499-502.
44. Moon.T. D. Cyproterone acetate for treatment of hot flashes after orchiectomy. J. Urol. 134 (1986), 155.
45. Moore, R. Y. Neuroendocrine mechanisms. Cells and systems. In Yen, S. S. C., R. B. Jaffe (Hrsg.) Reproductive Endocrinology. Physiology, Pathophysiology and Clinical Management. (Saunders Philadelphia 1991), 3-32.
46. O'Brien, A., R. Grainger, M. R. Butler Experience with Leuprorelin acetate as a depot formulation for prostate cancer in a long-term follow-up study. In Jakse, G., J. Wolff (Hrsg.) Endokrine Therapie des fortgeschrittenen Prostatakarzinoms (Springer Berlin 1992), 73-90.
47. Parmar. H., S. L Lightman. L Allen, R. H. Phillips. L Edwards. A. V. Schally Randomised controlled study of orchiectomy vs long-acting D-TRP-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 30 (1985), 1201 -1205.
48. Parra, R. 0., J. G. Gregory Treatment of post-orchiectomy hot flushes with transdermal administration of clonidine. J. Urol. 143 (1990), 753-754.
49. Prostate Cancer Trialists Collaborative Group Maximum androgen blockade in advanced prostate cancer. Lancet 346 (1995), 265.
50. Radlmaier, A., K. Bormacher, F. Neumann Hitzewallungen bei Endokrintherapie des Prostatakarzinoms. Modellvorstellung zu ihrer Genese. Akt. Ural. 20 (1989), 143 -147.
51. si Sharifi, R. S., M. Lee, L Qjeda, P. Ray, M. Stobnicki, P. Guinan. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of the prostate. Urology 26 (1985), 117-124.
52. Shoupe, D., R. A. Lobo Endogenous opioids in the menopause. Semin. Reprod. Endocrine!. 5 (1987), 199-206.
53. Smith,J. A. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J.Urol. 131 (1984), 1110-1111.
54. Smith, J. A. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.J. Urol. 152 (1994). 132-134.
55. Smith, P. H., M. R. G. Robinson Renaissance der Östrogentherapie beim fortgeschrittenen Prostatakarzinom. Urologe [A] 34 (1995), 393-397.
56. Smith, P. H., S. Suciu, M. R. G. Robinson, B. Richards, J. R. G. Bastable, R. W. Glashan, C. Bouffioux, B, Lardennois, R. E. Williams, M. DePauw, R. Sylvester A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer. J. Urol. 136 (1986), 619-623.
57. Stege, R., K. Carlström, P. O. Hedlund, A. Pousette, B. von Schoultz, P. Henriksson Intramuskuläres Depotöstrogen (Estradurin®) in der Behandlung von Patienten mit Prostatakarzinom. Urologe [A] 34 (1995), 398-403.
58. Steinfeld, A. D., C. Reinhard! Male climacteric after orchiectomy in patients with prostatic cancer. Urology 16 (1980), 620-622.
59. Studer, U. E. Fortgeschrittenes Prostatakarzinom - welche Hormontherapie wann? Urologe [A] 34 (1995), 361 -366.
60. Thorpe, S. C., S. Azmatullah. G.J. Fellows,]. C. Gingell, P. J. O'Boyle A prospective, randomised study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Europ. J. Urol. 29 (1996). 47-54.
61. Tyrrel, C. ]., J. E. Altwein, F. Kuppel, E. Varenhorst, G. Lunglmayr, F. Boccardo, I. M. Holdaway, J. M. Haefliger.J. P. jordaan. M. Sotarauta for the International Prostate Cancer Study Group A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone with flutamide in the treatment of advanced prostate cancer.]. Urol. 146 (1991), 1321.
62. Van Poppel, H., P. W. Werbrouck, L Baert Effect of estramustine phosphate on free androgens. Acta Urol. Belgica 58 (1990), 89 - 95.
63. Veterans Administration Cooperative Urological Research Group Carcinoma of the prostate. J. Urol. 98 (1967), 516-522.
64. Zagaja, G. P., D. B. Rukstalis, G. S. Gerber Transdermal estrogen in the treatment of hot flashes in men with prostate cancer. Proc. Amer. Urol. Ass. 155 [Suppl.],(1996),578A.